Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,247,521

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.91 +0.44 (0.22%) 4:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sheraz Mian headshot

Analyst Reports for Union Pacific, AbbVie & U.S. Bancorp

Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and U.S. Bancorp (USB).

    Roche (RHHBY) to Terminate Pacifica Bioscience Agreement

    Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.

      Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls

      Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.

        Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval

        Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.

          AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

          AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.

            Amgen/Allergan File for EU Approval of Avastin Biosimilar

            Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

              AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

              AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.

                Momenta/Shire's Humira Biosimilar Meets Study Objective

                Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.

                  The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                  The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay

                    Sheraz Mian headshot

                    Top Research Reports for Cisco, Amgen & NextEra Energy

                    Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).

                      Arpita Dutt headshot

                      Pharma Industry Outlook - November 2016

                      It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.

                        Mark Vickery headshot

                        Timeout from Q3 Earnings: GDP +2.9%

                        With GDP at 2.9% in Q3 (first read), we are seeing a snap-back from below-trend growth earlier in the year.

                          Sheraz Mian headshot

                          Stock Research Reports for Amazon, Boeing & MasterCard

                          Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), MasterCard (MA) and Boeing (BA).

                            Tracey Ryniec headshot

                            How Value Investors Can Buy Growth

                            Value and growth is a magical combination. Here???s how to get it.

                              Sheraz Mian headshot

                              Top Research Reports for Morgan Stanely, Union Pacific & AbbVie

                              Today's must-read reports are for AbbVie (ABBV), Morgan Stanley (MS) and Union Pacific (UNP).

                                5 Biotech Stocks to Bet on This Earnings Season

                                The happening biotech sector should be a good bet for investors.

                                  Stock Market News for April 07, 2016

                                  Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks